Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document a foreign private issuer reporting on Form 6-K and incorporating selected reports by reference into Form F-3 and Form S-8 registration statements. Recent disclosures cover shareholder communications, strategic direction, shareholder meeting results, proxy voting matters, registration-statement references, and governance records.
The filings also describe company activity across its medical business and newer technology initiatives, including the INSPIRA™ ART100 life-support platform, the HYLA™ blood sensor, an Additively Manufactured Electronics platform branded QTREX, and quantum-connectivity applications such as cryogenic interconnect structures for superconducting quantum systems. Formal reports include material agreements, purchase-order disclosures, capital-structure context, and risk-related business updates tied to these operating areas.
Inspira Technologies Oxy B.H.N. Ltd. announced a binding purchase order from a government customer for $27 million of ART100 systems, with the company stating that full payment will be received in 2025. The notice, filed as a Form 6-K and dated August 19, 2025, is signed by Chief Executive Officer Dagi Ben-Noon. The release communicates a material commercial win and a confirmed cash inflow timing without providing further operational or delivery details.